Autolus Therapeutics plc (AUTL) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

17/25

Growth 5 Margin 4 Expansion 3 Platform 2 Financial 3

latest quarter score

Earnings Reports

17
Autolus Therapeutics (AUTL) Q2 2026: AUCATZYL Sales Surge 119% Fuels Gross Margin Jump to 55%
August 11, 2026
12
Autolus Therapeutics (AUTL) Q1 2026: Gross Margin Turns Positive as Center Penetration Reaches 73
May 14, 2026
13
Autolist (AUTL) Q4 2025: 92% Real-World Remission Validates $120M+ Guidance and Expansion Ambitions
March 27, 2026
13
Autoless Therapeutics (AUTL) Q3 2025: Deferred Revenue Climbs to $7.6M, Signaling Uptick in CAR T Therapy Demand
November 12, 2025
11
Autolus (AUTL) Q2 2025: 46 U.S. Centers Activated, Setting Stage for Broad OB-Cell Uptake
August 12, 2025
12
Autolus (AUTL) Q1 2025: 39 Centers Activated, Laying Foundation for U.S. CAR-T Expansion
July 05, 2025
9
Autolus Therapeutics (AUTL) Q4 2024: 33 U.S. Centers Authorized, Accelerating CAR T Commercial Launch
March 20, 2025
Altalist Therapeutics (AUTL) Q3 2024: 30 Centers Activated for Orcatzel Launch, Reaching 60% of U.S. ALL Patients
November 12, 2024
Autolus (AUTL) Q2 2024: Cash Position Swells to $706M as OB-Cell Nears FDA Decision
August 08, 2024
Autolus Therapeutics (AUTL) Q1 2024: $600M Capital Infusion Fuels Commercial Launch and Autoimmune Pipeline Expansion
May 17, 2024
Autolus Therapeutics (AUTL) Q4 2023: BioNTech Alliance Adds $250M, Extending Cash Runway for OB-Cell Launch
March 14, 2024
9
Autolus Therapeutics (AUTL) Q3 2023: Nucleus Facility Validated for 2,000 Annual Batches, Unlocking Commercial Launch Readiness
November 02, 2023
Autolus Therapeutics (AUTL) Q2 2023: 76% Remission Rate in Felix Study Sets Up Pivotal BLA Filing
August 03, 2023
Autolus Therapeutics (AUTL) Q1 2023: $35M Blackstone Milestone Accelerates OB-Cell Launch Readiness
May 04, 2023
Autolus Therapeutics (AUTL) Q4 2022: $220M Blackstone Funding Secured as OB-Cell Durability Signals Competitive Edge
March 07, 2023

Browse all companies